{"id":"W2983284890","doi":"10.1200/jco.19.02107","title":"Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1014,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Pembrolizumab; Cohort; Colorectal cancer; Tolerability; Oncology; Microsatellite instability; Irinotecan; Progression-free survival; Clinical endpoint; Oxaliplatin; Response Evaluation Criteria in Solid Tumors; Cancer; Surgery; Phases of clinical research; Adverse effect; Chemotherapy; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003820299,0.0002767458,0.0029882,0.0002514583,0.00005677871,0.00001508449,0.0003741621,0.0002678471,0.0004275306],"category_scores_gemma":[0.000507247,0.0001894996,0.0004894733,0.000409887,0.0002532552,0.0001882548,0.0001388788,0.0007231069,0.000008112178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009700495,"about_ca_system_score_gemma":0.003173533,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001976298,"about_ca_topic_score_gemma":0.001504325,"domain_scores_codex":[0.9936345,0.0009558199,0.004162657,0.0004242735,0.0004630263,0.0003597058],"domain_scores_gemma":[0.9949256,0.001398471,0.002591553,0.0004199415,0.0004095693,0.0002549161],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3082857,0.2755408,0.1097114,0.0001365581,0.003245211,0.0007598472,0.003551851,0.0000302927,0.03006727,0.00001605949,0.0003678603,0.2682871],"study_design_scores_gemma":[0.391169,0.4691904,0.0983146,0.0003664415,0.001143039,0.0002591222,0.002370868,0.0001820757,0.00162534,0.00004792332,0.03506525,0.0002659979],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931742,0.001987815,0.000002274912,0.001051897,0.001609577,0.001769879,0.00003002584,0.00001132288,0.0003630102],"genre_scores_gemma":[0.996576,0.001752985,0.0006027542,0.0005501934,0.000150366,0.00003017022,0.000007178211,0.00002781316,0.0003025786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2680211,"threshold_uncertainty_score":0.7727568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1353295079761783,"score_gpt":0.4909100416450203,"score_spread":0.355580533668842,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}